Navigation Links
Favrille to Host Conference Call and Live Webcast to Discuss First Quarter 2008 Financial Results on May 8, 2008
Date:5/1/2008

SAN DIEGO, May 1 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, announced today that it will host a conference call and live webcast at 5:00 p.m. Eastern Time on Thursday, May 8, 2008 to discuss the Company's first quarter 2008 financial results. A press release will be issued after the U.S. stock markets close that day.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080404/LAF521LOGO)

A live audio webcast of management's presentation will be available on the Investor Relations section of the Company's web site at http://www.favrille.com. Alternatively, callers may participate in the conference call by dialing (888) 713-4205 or (617) 213-4862, passcode 61931952. To pre-register for this call, please go to https://www.theconferencingservice.com/prereg/key.process?key=PFYXYBR33. Callers who pre-register will be given a unique PIN to gain immediate access to the call and bypass the live operator. You may pre-register at any time, including up to and after the call start time. A telephone replay of the call will also be available for 48 hours. The telephone replay can be accessed by dialing (888) 286-8010 or (617) 801-6888, passcode 61738291.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, Specifid(TM) (formerly FavId(R)), is based upon unique genetic information extracted from a patient's tumor. Specifid is currently under investigation in a Phase 3 registration trial for patients with fol
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
2. Favrille Announces $21.1 Million Registered Direct Offering
3. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
4. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
5. Favrille to Present at BIO InvestorForum
6. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
7. Favrille CEO to Present at Bear Stearns Healthcare Conference
8. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
9. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
10. Gen-Probe to Webcast Presentation at Deutsche Bank 33rd Annual Health Care Conference
11. InterMune to Present at Deutsche Bank Health Care Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...,Nov.24/PRNewswire-FirstCall/--DowAgroSciencesCana...s,adivisionofThompsonsLimitedofBlenheim,Ontario.Th...nces,currentseedsbusinessasthecompanyanticipatesth...SciencesHerbicideTolerantTraitTechnologyincornin20... ,, "Thisacquisitionbringstogethertwostrongprog...
(Date:11/24/2009)...-Asia/--NODPharmaceuticalsInc.announced,theUSPaten...cationfor,itsnano-particleoraldeliveryorNODtechnol...htoincorporatepeptidesor,proteinsintobio-adhesiven...administeredasinjections.NODtechnologyisaplatformt...ssuchasinsulin,interferon,growthhormone,exenatide...
(Date:11/24/2009)...beenmetforpatientswithadvanced-stage,orrecurrenten...re-FirstCall/-AEternaZentarisInc.(NASDAQ: AEZS ;TS...nyfocusedonendocrinetherapyandoncology,todayannoun...etedcytotoxicpeptideconjugate,AEZS-108(formerlyAN-...ancer.Inapersonalizedhealthcareapproach,thestudyse...
(Date:11/24/2009)...ewswire/--HealthRoboticstodayannounced,thatithasfo...nvestors.ThisrecentlyformedToronto-basedcompanywil...illmarket,install,andsupport,HealthRobotics,i.v.Ro...yproductofferingsi.v.STATION(TM),i.v.SOFT(TM),andO...istanceonan"asneeded,basis"toitsstrategicpartnersh...
Breaking Biology Technology:Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2
...h Park MADISON OpGen, Inc. has added two new me...omas Pyle. The company is looking to bring in seas...he next level, according to Dan Broderick, managin... , ,They bring lots of experience with company ope...hey have long, successful careers in business and ...
...y figures show no reported venture investment acti...ear. Both total venture capital and initial ventur...as released by PricewaterhouseCoopers, Thomson Ven...sociation. Ten other states also showed $0 activit...money, according to the survey, with California re...
...ializing in patient-specific molecular data and pe...ts president and chief executive officer, it annou...esident and CEO of Pel-Freez Clinical Systems , l...ar biology and serologic products for solid organ ...icant growth and eventual acquisition under Langel...
Other Biology Technology:OpGen adds Thomas Pyle and James Ogle to board of directors 2MoneyTree Survey reports no venture investment activity in Wisconin in Q2 2MoneyTree Survey reports no venture investment activity in Wisconin in Q2 3MoneyTree Survey reports no venture investment activity in Wisconin in Q2 4MoneyTree Survey reports no venture investment activity in Wisconin in Q2 5MoneyTree Survey reports no venture investment activity in Wisconin in Q2 6
(Date:11/24/2009)... atomic-level action of a remarkable class of ring...rchers with the Lawrence Berkeley National Laborat...n crystallography beamline at the Advanced Light S...es in gene expression and replication, and are vit...l as infectious agents, such as the human papillom...
(Date:11/24/2009)...at constitutes fish food is a matter of debate. A ...fish get almost 50 percent of their carbon from tr...ween the terrestrial and aquatic ecosystems. , B...shows this is not likely to be true. Algae provide...e, according to research published this week in th...
(Date:11/23/2009)...hington, D.C. The community-associated strain of ...ria resistant to most common antibioticsposes a fa...is making its way into hospitals, according to a s... Diseases . , The new threat is easily picked u...aces and has increased the overall burden of MRSA ...
Breaking Biology News(10 mins):Atomic-level snapshot catches protein motor in action 2Atomic-level snapshot catches protein motor in action 3Atomic-level snapshot catches protein motor in action 4Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3New study finds MRSA on the rise in hospital outpatients 2IBM Analytics Expands To Help Governments Around World Build Smarter Systems 54203 1IBM Analytics Expands To Help Governments Around World Build Smarter Systems 54203 2IBM Analytics Expands To Help Governments Around World Build Smarter Systems 54203 3IBM Analytics Expands To Help Governments Around World Build Smarter Systems 54203 4Plasma Protein Therapeutics Association Urges CMS For Appropriate Hospital Outpatient Drug Reimbursement 54200 1Plasma Protein Therapeutics Association Urges CMS For Appropriate Hospital Outpatient Drug Reimbursement 54200 2Plasma Protein Therapeutics Association Urges CMS For Appropriate Hospital Outpatient Drug Reimbursement 54200 3BP and Martek Biosciences Enter Joint Development Agreement to Deliver Advanced Biodiesels 13502 1BP and Martek Biosciences Enter Joint Development Agreement to Deliver Advanced Biodiesels 13502 2BP and Martek Biosciences Enter Joint Development Agreement to Deliver Advanced Biodiesels 13502 3BP and Martek Biosciences Enter Joint Development Agreement to Deliver Advanced Biodiesels 13502 4
...T LAFAYETTE, Ind. - Chemical engineers have develo...an inexpensive way of making diamondlike crystals ...logies. , The method, developed at Purdue Univers...licon template containing precisely spaced holes t...air. The template is immersed in water on top of w...
...orld was in shock when in 2001 the Talibans destro...han region of Bamiyan. Behind those statues, there...5th to 9th century A.D. The caves also suffered fr...atural environment, but today they have become the...ed, thanks to experiments performed at the Europea...
...er twenty-five years of investigating, analyzing, ...ers, neighbors, and even surviving victims, crimin...of the worlds most respected experts on the motiva...n SERIAL KILLERS AND SADISTIC MURDERERS: UP CLOSE ...is wealth of experience with the criminal mind to ...
Other Biology News:Findings a step toward making new optical materials 2Findings a step toward making new optical materials 3Findings a step toward making new optical materials 4Findings a step toward making new optical materials 5Synchrotron light unveils oil in ancient Buddhist paintings from Bamiyan 2A chilling glimpse inside the minds of dangerous criminals 2
Alkaline Phosphatase (E. coli C75) from GE Healthcare, formerly Amersham Biosciences
...and cDNA Labeling Kit with CyScribe GFX Purificati...ication of Cy3- and Cy5-labeled cDNA.Optimized rea...ling and purification.Flexible and optimized proto... with either Cy3- or Cy5-labeled nucleotides.Relia...
...ling Kit with CyScribe GFX Purification Kit, 24 re...3- and Cy5-labeled cDNA.Optimized reagents are pac...fication.Flexible and optimized protocols can be u...Cy3- or Cy5-labeled nucleotides.Reliable purificat...
Canine serum from Equitech-Bio
Biology Products: